Market Research Logo

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2016

Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Review, H2 2016’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic’s Syndrome)
    • The report reviews pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Neuromyelitis Optica (Devic’s Syndrome) therapeutics and enlists all their major and minor projects
    • The report assesses Neuromyelitis Optica (Devic’s Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic’s Syndrome) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Neuromyelitis Optica (Devic’s Syndrome) Overview
    Therapeutics Development
    Pipeline Products for Neuromyelitis Optica (Devic’s Syndrome) - Overview
    Pipeline Products for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis
    Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics under Development by Companies
    Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics under Investigation by Universities/Institutes
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Neuromyelitis Optica (Devic’s Syndrome) - Products under Development by Companies
    Neuromyelitis Optica (Devic’s Syndrome) - Products under Investigation by Universities/Institutes
    Neuromyelitis Optica (Devic’s Syndrome) - Companies Involved in Therapeutics Development
    Acorda Therapeutics, Inc.
    Alexion Pharmaceuticals Inc
    Biogen Inc
    Bionure Farma, S.L.
    Chugai Pharmaceutical Co., Ltd.
    Clene Nanomedicine, Inc.
    HanAll Biopharma Co., Ltd.
    Karus Therapeutics Limited
    LFB S.A.
    Marathon Pharmaceuticals, LLC
    MedImmune, LLC
    Opexa Therapeutics, Inc.
    Shire Plc
    Takeda Pharmaceutical Company Limited
    Neuromyelitis Optica (Devic’s Syndrome) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    ANV-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BN-201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    C1 esterase inhibitor (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cladribine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CNMAU-8 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    D-15107 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    dalfampridine ER - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    eculizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HL-161 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    inebilizumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KA-1463 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OPX-212 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rituximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SA-237 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule for Neuromyelitis Optica - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ublituximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects
    Neuromyelitis Optica (Devic’s Syndrome) - Product Development Milestones
    Featured News & Press Releases
    Aug 26, 2016: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
    Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)
    Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program
    Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol
    May 08, 2015: Initiation Of Phase I Clinical Program
    Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting
    Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned
    Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
    Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
    Aug 27, 2014: Clene Files Investigational New Drug Application With FDA
    Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis
    Apr 01, 2014: Clene Nanomedicine Requests Pre-IND Meeting With FDA
    Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles
    Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion
    Jul 16, 2013: Alexion’s Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2016
    Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Investigation by Universities/Institutes, H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Acorda Therapeutics, Inc., H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Biogen Inc, H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Bionure Farma, S.L., H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Clene Nanomedicine, Inc., H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Karus Therapeutics Limited, H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by LFB S.A., H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by MedImmune, LLC, H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Opexa Therapeutics, Inc., H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Shire Plc, H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Neuromyelitis Optica (Devic’s Syndrome) - Dormant Projects, H2 2016
    List of Figures
    Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome), H2 2016
    Number of Products under Development for Neuromyelitis Optica (Devic’s Syndrome) - Comparative Analysis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Investigation by Universities/Institutes, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report